Takeda and Sanofi join Milner Therapeutics Consortium

The Milner Therapeutics Institute are excited to announce that two new pharma partners — Takeda and Sanofi — have joined the Milner Consortium in the past month.

Now with 14 pharma partners and 3 academic partners, this is the largest cross-sector Biomedical Consortia in the UK that is working in target discovery across multiple disease areas and emerging technologies. Since 2015, the Consortium has initiated 37 research projects across the University of Cambridge, Babraham and Wellcome Sanger Institutes, bringing a research investment of  over £9m.

Sanofi has its UK R&D base on the Babraham Research Campus, south of Cambridge, which is focused on the discovery of novel therapeutics for the treatment of chronic inflammatory  and autoimmune diseases, and also brings expertise around antibody discovery and antibody engineering. Chris Schiering (Director of Translational Biology, Immune Regulation & Tolerance Cluster, I&I Research) and Mark Peakman (Head of Immune Regulation & Tolerance Cluster, I&I Research) will represent Sanofi on the Milner Innovation Board.

Takeda aims to discover and deliver life-transforming treatments in core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Takeda’s global Research and Development (R&D) center is based in Cambridge, Massachusetts with R&D Research Labs in San Diego, California, and Shonan, Japan and Regional R&D Centers and local sites across the globe. Peter Maycox (Director of External Innovation, Neuroscience Research) will represent Takeda on the Milner Innovation Board with an additional representative joining in the coming months.


More news and updates 

Stablepharma secures Innovate UK grant, bridge funding round to launch

This joint Innovate UK grant will advance the clinical development of Stablepharma’s lead candidate, SPVX02, a fridge-free vaccine for the prevention of Tetanus and Diphtheria, validating its safety and efficacy through first-in-human clinical trials.

Broken String Biosciences closes $15 million Series A funding round

Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design,  has closed a $15 million Series A investment round.

CPI launches RNA Centre of Excellence

UK's first RNA therapeutic innovation center opens in Darlington, driving cutting-edge vaccine and therapeutic development.

UK rare disease research landscape mapped for first time

A detailed view of rare disease research in the UK has been captured for the first time in a new report published today. It reveals over £1.1 billion has been invested by Government and charities over a five-year-period.

Life Science Group: A finalist for the Innovate UK KTP Awards 2023

Life Science Group (LSG) proudly announces its selection as a finalist in the Impact and Transformation Award category of the esteemed 2023 Innovate UK Knowledge Transfer Partnership (KTP) Best of the Best Awards.

Advancing early lung cancer diagnosis

Life Science Group are delighted to be part of a consortium, led by Welsh scientists at Aberystwyth University, to develop a novel and potentially disruptive lateral flow device for the detection of early-stage lung cancer.

Accelerating innovation in cell culture solutions through collaborative funding

Life Science Group Ltd (LSG) is excited to announce that its joint application with the Mary Lyon Centre (MLC) at MRC Harwell to the MRC National Mouse Genetics Network (NMGN) Business Engagement Fund has been approved in principle, pending the signature of the relevant agreements.

FDA grants US Orphan Drug Designation to Medannex's MDX-124

Medannex Ltd announced today that its novel therapy, MDX-124, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA).

AlveoGene launches to develop inhaled gene therapies for rare respiratory disorders

New gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC)

AstraZeneca commits £100 million to advance UK energy efficiency

15-year agreement with Future Biogas will provide 100 GWh of green gas (biomethane) annually, equivalent to meet the heat demands of over 8,000 homes


More within